Research ExplorerPublicationsImpact of expression differences of kallikrein-related pepti...

Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer

Standard

Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. / Dorn, J; Harbeck, N; Kates, R; Gkazepis, A; Scorilas, A; Soosaipillai, A; Diamandis, E; Kiechle, M; Schmalfeldt, B; Schmitt, M.

In: ANN ONCOL, Vol. 22, No. 4, 04.2011, p. 877-83.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Dorn, J, Harbeck, N, Kates, R, Gkazepis, A, Scorilas, A, Soosaipillai, A, Diamandis, E, Kiechle, M, Schmalfeldt, B & Schmitt, M 2011, 'Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer', ANN ONCOL, vol. 22, no. 4, pp. 877-83. https://doi.org/10.1093/annonc/mdq462

APA

Dorn, J., Harbeck, N., Kates, R., Gkazepis, A., Scorilas, A., Soosaipillai, A., Diamandis, E., Kiechle, M., Schmalfeldt, B., & Schmitt, M. (2011). Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. ANN ONCOL, 22(4), 877-83. https://doi.org/10.1093/annonc/mdq462

Vancouver

Dorn J, Harbeck N, Kates R, Gkazepis A, Scorilas A, Soosaipillai A et al. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. ANN ONCOL. 2011 Apr;22(4):877-83. https://doi.org/10.1093/annonc/mdq462

Bibtex

@article{3580be263cf44a7fa0096d281b3e1fb5,
title = "Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer",
abstract = "BACKGROUND: Primary tumor levels of serine proteases of the kallikrein-related peptidases (KLK) family as well as urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 impact disease course in ovarian cancer. The changes in levels of these factors from primary tumor to omentum metastasis ('level differentials') could thus be associated with metastastic processes.PATIENTS AND METHODS: Protein levels of seven tissue KLK (KLK5-8, 10, 11, 13), uPA, and PAI-1 were determined in extracts of primary tumor tissue and corresponding omentum metastasis of 54 ovarian cancer patients.RESULTS: Higher level differentials of KLK5-8, 10-11, and uPA were associated with residual tumor >10 mm. Residual tumor and larger level differentials of KLK5-7, 10, and uPA were associated with disease progression in the whole cohort. Remarkably, level differentials of KLK5-8 and 10-11 strongly impacted disease progression even in patients with residual tumor mass ≤10 mm; hence, the observed impact of level differentials in KLK5-7 and 10 on disease progression was not simply attributable to their association with surgical success.CONCLUSION: Since they impact both surgical outcome and survival in advanced ovarian cancer, measurement of level differentials could support clinical decisions on surgical and systemic therapy or help in patient selection for novel targeted therapies.",
keywords = "Adult, Aged, Aged, 80 and over, Disease Progression, Female, Humans, Kallikreins, Middle Aged, Neoplasm Staging, Omentum, Ovarian Neoplasms, Peptide Hydrolases, Peritoneal Neoplasms, Plasminogen Activator Inhibitor 1, Prognosis, Retrospective Studies, Tumor Markers, Biological, Urokinase-Type Plasminogen Activator",
author = "J Dorn and N Harbeck and R Kates and A Gkazepis and A Scorilas and A Soosaipillai and E Diamandis and M Kiechle and B Schmalfeldt and M Schmitt",
note = "{\textcopyright} The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.",
year = "2011",
month = apr,
doi = "10.1093/annonc/mdq462",
language = "English",
volume = "22",
pages = "877--83",
journal = "ANN ONCOL",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer

AU - Dorn, J

AU - Harbeck, N

AU - Kates, R

AU - Gkazepis, A

AU - Scorilas, A

AU - Soosaipillai, A

AU - Diamandis, E

AU - Kiechle, M

AU - Schmalfeldt, B

AU - Schmitt, M

N1 - © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

PY - 2011/4

Y1 - 2011/4

N2 - BACKGROUND: Primary tumor levels of serine proteases of the kallikrein-related peptidases (KLK) family as well as urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 impact disease course in ovarian cancer. The changes in levels of these factors from primary tumor to omentum metastasis ('level differentials') could thus be associated with metastastic processes.PATIENTS AND METHODS: Protein levels of seven tissue KLK (KLK5-8, 10, 11, 13), uPA, and PAI-1 were determined in extracts of primary tumor tissue and corresponding omentum metastasis of 54 ovarian cancer patients.RESULTS: Higher level differentials of KLK5-8, 10-11, and uPA were associated with residual tumor >10 mm. Residual tumor and larger level differentials of KLK5-7, 10, and uPA were associated with disease progression in the whole cohort. Remarkably, level differentials of KLK5-8 and 10-11 strongly impacted disease progression even in patients with residual tumor mass ≤10 mm; hence, the observed impact of level differentials in KLK5-7 and 10 on disease progression was not simply attributable to their association with surgical success.CONCLUSION: Since they impact both surgical outcome and survival in advanced ovarian cancer, measurement of level differentials could support clinical decisions on surgical and systemic therapy or help in patient selection for novel targeted therapies.

AB - BACKGROUND: Primary tumor levels of serine proteases of the kallikrein-related peptidases (KLK) family as well as urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 impact disease course in ovarian cancer. The changes in levels of these factors from primary tumor to omentum metastasis ('level differentials') could thus be associated with metastastic processes.PATIENTS AND METHODS: Protein levels of seven tissue KLK (KLK5-8, 10, 11, 13), uPA, and PAI-1 were determined in extracts of primary tumor tissue and corresponding omentum metastasis of 54 ovarian cancer patients.RESULTS: Higher level differentials of KLK5-8, 10-11, and uPA were associated with residual tumor >10 mm. Residual tumor and larger level differentials of KLK5-7, 10, and uPA were associated with disease progression in the whole cohort. Remarkably, level differentials of KLK5-8 and 10-11 strongly impacted disease progression even in patients with residual tumor mass ≤10 mm; hence, the observed impact of level differentials in KLK5-7 and 10 on disease progression was not simply attributable to their association with surgical success.CONCLUSION: Since they impact both surgical outcome and survival in advanced ovarian cancer, measurement of level differentials could support clinical decisions on surgical and systemic therapy or help in patient selection for novel targeted therapies.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Disease Progression

KW - Female

KW - Humans

KW - Kallikreins

KW - Middle Aged

KW - Neoplasm Staging

KW - Omentum

KW - Ovarian Neoplasms

KW - Peptide Hydrolases

KW - Peritoneal Neoplasms

KW - Plasminogen Activator Inhibitor 1

KW - Prognosis

KW - Retrospective Studies

KW - Tumor Markers, Biological

KW - Urokinase-Type Plasminogen Activator

U2 - 10.1093/annonc/mdq462

DO - 10.1093/annonc/mdq462

M3 - SCORING: Journal article

C2 - 20924077

VL - 22

SP - 877

EP - 883

JO - ANN ONCOL

JF - ANN ONCOL

SN - 0923-7534

IS - 4

ER -